Refine by
Prescription Drug Articles & Analysis
39 news found
Application Fields Pharmaceutical cold-formed blister packaging Moisture-proof, oxidation-proof packaging for tablets, capsules, and powders Packaging for high-end biopharmaceuticals and prescription drugs Sealed packaging for specialty chemicals and healthcare supplements Company Profile We specialize in providing one-stop packaging material solutions for ...
Our program with Perigon builds on this success by offering patients a more convenient way to consistently obtain access to their DYANAVEL XR extended-release tablet prescription.” Since the November 2021 approval of DYANAVEL XR extended-release tablets, Tris Pharma has seen a consistent increase in prescription volume and taken steps to manage ...
The goal is to provide drug manufacturers with accurate and reliable results. Moreover, the technology used in this process is capable of detecting impurities and other contaminants in prescription drug formulations. Pre-prescription studies are crucial for the formulation prescribing process, which is important for assessing the ...
CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy ...
(“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. ...
GlobalData predicts that the global dry eye drug market will reach approximately US$11 billion in 2028, with a compound annual growth rate of 10.6% from 2018 to 2028. ...
(“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. ...
” In March 2022, the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for futibatinib in the treatment of patients with previously treated locally advanced or metastatic CCA harboringFGFR2 gene rearrangements, including gene fusions. The FDA provided an anticipated Prescription ...
An ODD brings several unique advantages, from a cost reduction in drug development, to an accelerated review process and market exclusivity for 10 years. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome ...
This strategy does not work for prescription drug donations as they require a medical order for sale to a private customer; a prospective donor can’t simply walk into Walgreens and buy epinephrine, heparin, insulin, Zofran, Dilaudid or ketamine. ...
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced its support and recognition of the DEA’s National Prescription Drug Take Back Day on April 30, 2022. ...
U.S. Indications DUPIXENT is a prescription medicine used: to treat adults and children 6 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ...
U.S. Indications DUPIXENT is a prescription medicine used: to treat adults and children 6 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ...
PRINCETON, N.J., MARCH 30, 2022 – Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for futibatinib in the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboringFGFR2 ...
The clinical trial has been authorized by Health Canada, who also recently approved an amendment to the research protocol to increase the dosage of the study drug up to 100 mg of CBD to be assessed in the study. Under the collaboration, Tetra will supply the synthetic cannabidiol investigational drug products and placebo and in exchange will gain access to ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced today that it has executed a non-binding term sheet with Avicanna Inc. ...
Jelmyto is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. ...
With the addition of India, Neuropathix now has eight (8) prominent pharmaceutical jurisdictions that include the U.S., European Union (16 countries), Canada, Australia, Japan, Russia, and China, with Brazil currently pending. The global market for prescription drug sales are expected to see a compound annual growth rate (CAGR) of 8.9% from 2018 to 2026. ...
November 2020?by the?U.S. Food and Drug Administration?(FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing and in July ...